



King Pharmaceuticals, Inc.
Research and Development
CentreGreen Two, Suite 300
4000 CentreGreen Way
Cary, NC 27513

Eric G. Carter, PhD, MD
Chief Science Officer

June 4, 2008

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals[®], Inc. has decided to discontinue the manufacture of CORTISPORIN[®] Otic Suspension (neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP). CORTISPORIN[®] Otic Suspension will remain available through pharmacies and wholesalers until current supplies are depleted. This decision is based upon many factors, including our understanding of current medical therapy and the availability of alternative therapies.

CORTISPORIN[®] Otic Suspension is distributed through King Pharmaceuticals[®], Inc. No additional product will be available after King, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

CORTISPORIN[®] Otic Suspension (neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP) is a sterile antibacterial and anti-inflammatory suspension indicated for the treatment of bacterial infections of the external auditory canal caused by microorganisms susceptible to the action of antibiotics and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

Important Safety Information:

CORTISPORIN[®] Otic Suspension is contraindicated in herpes simplex, vaccinia, and varicella infections. Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days. Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported. Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. The reaction occurring most often is allergic sensitization. Stinging and burning have been reported rarely when his drug has gained access to the middle ear.

Sincerely,

A handwritten signature in black ink that reads "Eric Carter".

Eric Carter, PhD, MD
Chief Science Officer

Please see accompanying full Prescribing Information.

CORTISPORIN is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals[®], Inc.

Copyright © 2008 King Pharmaceuticals[®], Inc. All rights reserved. MSB0005 Printed in U.S.A. 6/2008